Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Immunotherapy for mesothelioma: rationale and new approachesJoshua E Reuss, Patrick M FordeCurrent Oncology Reports|May 17, 2020
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and BeyondJoshua E Reuss, Karthik Suresh, Jarushka NaidooAnnual Review of Medicine|October 26, 2018
PD-1 Blockade in Early-Stage Lung CancerSamuel Rosner, Joshua E Reuss, Patrick M FordeClinical Advances in Hematology & Oncology : H&O|May 28, 2024
Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?Joshua E Reuss, Samuel Rosner, Benjamin P LevyClinical Lung Cancer|August 23, 2021
Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future DevelopmentsJoshua E Reuss, Laura Gosa, Stephen V LiuFrontiers in Oncology|May 20, 2020
Oral Chemotherapy for Treatment of Lung CancerSushma Jonna, Joshua E Reuss, Chul Kim, et al.Anti-Cancer Drugs|September 11, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancerKara M Schenk, Joshua E Reuss, Karin Choquette, et al.Current Oncology Reports|October 5, 2022
Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic ClassJennifer A Marks, Molly Wilgucki, Stephen V Liu, et al.JTO Clinical and Research Reports|September 30, 2021
<i>EML4-ALK</i> Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case ReportXinyu von Buttlar, Joshua E Reuss, Stephen V Liu, et al.Current Oncology Reports|May 30, 2023
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung CancerJay Parekh, Kaushal Parikh, Joshua E Reuss, et al.Pageof 6